Endocrine Gland Neoplasms clinical trials

The registry lists 49 studies for Endocrine Gland Neoplasms across more than 10 countries. 14 are recruiting or about to start. 5 of them are mainly about Endocrine Gland Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its 35 narrower conditions too, such as Pancreatic Neoplasms: 9,263 studies, 2,307 open.

Get an email when these change. Save the Endocrine Gland Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 23
Recruiting: 12
Terminated: 4
Active, not recruiting: 4
Status unknown: 4
Not yet recruiting: 2

Phase

Phase 2: 15
Phase 1: 13
Phase 3: 3
Early Phase 1: 1

Where

United States: 29
France: 12
Italy: 10
Spain: 9
Germany: 9
Belgium: 9

Who runs them

National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Syndax Pharmaceuticals (2) · Catalysis SL (2) · Medical University of Vienna (2) · KU Leuven (2) · Sumitomo Pharma America, Inc. (2) · Eli Lilly and Company (2)

What is being tested here

Drugs under test in Endocrine Gland Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Psilocybin	1	0	2
Repotrectinib	1	0	1
Selpercatinib	0	0	2
Albumin-Bound Paclitaxel	0	1	2
Paclitaxel	0	1	2
Ocoxin	0	0	2
Entinostat	0	0	2
Niraparib	0	0	2
Bevacizumab	0	0	2
Pralsetinib	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Angiogenesis inhibitors 3

Coming up

0phase 3 studies under way

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Dec 2026Establishment of a Tumor Bank for Tissue Samples · Medical University of Vienna
Dec 2026Establishment of a Tumor Bank for Blood Samples · Medical University of Vienna
Dec 2026Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer · University Health Network, Toronto
May 2027Understanding New Cachexia Subtypes Through Observational Epidemiological Research · Kaiser Permanente
May 2027Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors · University of California, Irvine

Who these studies take

Of the 12 Endocrine Gland Neoplasms studies recruiting now, 10 (83%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (17%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	2 (17%)	2 (17%)
18	12 (100%)	12 (100%)
30	12 (100%)	12 (100%)
40	12 (100%)	12 (100%)
50	12 (100%)	12 (100%)
65	12 (100%)	12 (100%)
75	12 (100%)	12 (100%)
85	12 (100%)	12 (100%)

Across all 49 studies, recruiting or not: 12% stop at 75 or younger and 10% at 65; 24% take children; 10% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 15, 2026.

Results posted1

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNov 5, 2026NCT01552434

Studies

Recruiting first, then most recently updated. Showing 49 of 49. search them.